Compare PTCT & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PTCT | APGE |
|---|---|---|
| Founded | 1998 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 4.7B |
| IPO Year | 2006 | 2023 |
| Metric | PTCT | APGE |
|---|---|---|
| Price | $72.40 | $91.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 13 |
| Target Price | $80.65 | ★ $109.67 |
| AVG Volume (30 Days) | 774.1K | ★ 1.1M |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 264.48 | N/A |
| EPS | ★ 7.78 | N/A |
| Revenue | ★ $264,734,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $19.02 | N/A |
| P/E Ratio | $9.30 | ★ N/A |
| Revenue Growth | ★ 36.19 | N/A |
| 52 Week Low | $35.95 | $33.30 |
| 52 Week High | $87.50 | $95.32 |
| Indicator | PTCT | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 58.99 | 71.61 |
| Support Level | $69.81 | $73.06 |
| Resistance Level | $79.59 | N/A |
| Average True Range (ATR) | 2.25 | 3.35 |
| MACD | 0.47 | 0.64 |
| Stochastic Oscillator | 81.77 | 77.92 |
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.